Research · 9 min read
Hormone therapy dispensing has more than doubled: what the new JAMA data mean for you
More menopause hormone therapy prescriptions are being dispensed each month than in 2023, according to a new national analysis reported by Science News. On November 19, 2026, JAMA published "Trends in Menopause Hormone Therapy," a cross-sectional study by Dana O. Sarnak, Wen Shen and G. Caleb Alexander of Johns Hopkins, using national pharmacy dispensing data to look at menopause hormone therapy in the United States by age group, formulation and route.
Science News, reporting on that paper the same day, says monthly dispensing to women aged 40 to 74 more than doubled since 2023, growing from 2 million to 4.9 million. The same account says the researchers used population data to estimate a dispensing rate for this age group, which rose from 28 prescriptions per 1,000 women to 67 prescriptions per 1,000 over the period studied. Those counts are Science News's report of the JAMA results. We confirmed the paper's citation details in PubMed and Crossref — title, authors, DOI 10.1001/jama.2026.22619, PMID 43056087, published online November 19, 2026, and ahead of print — but we could not independently read the JAMA full text for this draft, so we are not treating the figures as verified from the paper itself.
The numbers describe monthly dispensing, not a count of unique people. One person can have more than one fill in a month, and Science News notes that the underlying data are aggregate. A higher dispensing rate is not, by itself, a reason to start or stay on hormone therapy. It is a reason to look carefully at what changed, which products are driving the growth, and how to plan if the form you use is hard to find.
This article is for education. It is not medical advice. What follows walks through why more people may be asking about hormone therapy now, which products account for the growth while pills stayed flat, why a progestogen matters if you have a uterus and use systemic estrogen, and how to plan around the patch shortage without repeating our earlier guide.
Why dispensing may be rising now
Science News reports that the increase in the JAMA analysis began in 2024. The rise continued in 2025, before and after the Food and Drug Administration's November 2025 labeling action on boxed warnings, and into 2026. The study, Science News says, was not designed to determine what is behind the increase.
That timing matters. It means the rise in dispensing had already started before FDA asked manufacturers, in November 2025, to change labeling on menopausal hormone therapy products. FDA's September 3, 2026, update on estradiol transdermal patches does say that demand increased following that November 2025 action, in which FDA requested that manufacturers "make changes to the labeling to remove boxed warnings about a probable risk of breast cancer, cardiovascular disease, and probable dementia for patients receiving menopausal hormone therapy products for menopause." That is FDA's account of its request and of the timing of the demand increase. It is not the same as saying every boxed warning was removed from every product, or that the JAMA doubling is solely a result of the label change. The change is product by product, and some important warnings remain. We walked through what actually changed, and what did not, in our boxed-warning explainer.
Updated clinical guidance is part of the context as well. Science News notes that medical groups such as the Menopause Society have recommended menopause hormone therapy for women with symptoms who are younger than 60 or within 10 years of the start of menopause, absent certain risk factors including prior breast cancer and stroke. In October 2026, the American College of Obstetricians and Gynecologists published Clinical Practice Guideline 13 on the management of menopause-related vasomotor, sleep, and mood symptoms. ACOG's public news release does not call hormone therapy "first-line." It says initiating hormone therapy should be based on shared decision-making, taking into account symptoms, benefits and risks based on age, medical history, and baseline risks of cardiovascular disease, breast cancer, and venous thromboembolism, and the person's treatment goals. If hormone therapy is selected, ACOG recommends starting before age 60 or within 10 years of the start of spontaneous menopause in people without contraindications. The release also reviews nonhormonal options for people who cannot use hormones or prefer not to. Coauthor Dr. Robert P. Kauffman said, "Hormone therapy can be a great option—and in many cases, the best option—but may not be appropriate or helpful for every person experiencing menopausal symptoms." Our October explainer covers that guidance in more detail, including timing. For more on who may not be a candidate, see who shouldn't take hormone therapy and whether there is an age limit.
Awareness is the third piece often named. In the Science News report, Sarnak, who is also an author of the JAMA paper, said, "Greater attention to women's health, updated medical guidance supporting individualized menopause hormone therapy and social media may all be contributing to increased interest." Science News adds that, anecdotally, her clinician colleagues report more patients seeking menopause care, and that it is possible evidence about the safety and effectiveness of hormone therapy for symptoms such as hot flashes is reaching more women. Those are possible explanations, not findings the JAMA study was designed to prove.
Hormone therapy isn't right for everyone: depending on age, timing, health history and the type used, it can raise the risk of blood clots, stroke and breast cancer, and estrogen without a progestogen raises the risk of uterine cancer in people who have a uterus.
ACOG's October guidance also addresses sleep and mood symptoms related to menopause, alongside hot flashes and night sweats. Mood changes can be part of the transition, and they can also have other causes. A conversation with a clinician is the place to sort that out.
If you are thinking about harming yourself or ending your life, or you are in emotional crisis, call or text 988 (the 988 Suicide & Crisis Lifeline) or chat at 988lifeline.org. It is free, confidential and available 24/7. If you or someone else is in immediate danger or having a medical emergency, call 911.
Where the growth is: transdermal and vaginal estrogen, and progesterone
Science News, summarizing the JAMA findings, says product use increased for transdermal and vaginal estrogen and for progesterone products, while the use of oral formulations remained stable. Transdermal estrogen includes patches and gels. That split is the main story in the new data: the growth is not a uniform rise in every form of hormone therapy. Pills, in this account, stayed flat.
The paper itself, as described in its PubMed and Crossref records, looked at formulation and route. We cannot add dose-by-dose or brand-by-brand detail from the JAMA full text, because we could not read it. We also are not treating a different Johns Hopkins clinic analysis, or other 2026 studies of hormone therapy trends, as if they were this JAMA dispensing paper. The figures in this post are the ones Science News reported from this study.
The pattern still has a practical meaning. If you and a clinician are talking about hormone therapy, the conversation is not only "yes or no." It is also which hormone, which route, and whether a progestogen belongs in the plan. A patch or gel is not automatically interchangeable with a pill, and vaginal estrogen is not the same as systemic therapy used for hot flashes. Our guide to types of hormone therapy is the place for that comparison. What is appropriate for one person can be a poor fit for another.
Why progesterone matters if you have a uterus
Science News, still summarizing the JAMA results, notes that women who have their uterus need to take progesterone along with estrogen, and that use of progesterone products rose along with transdermal and vaginal estrogen.
The more precise clinical point, and the one in our house risk language above, is about systemic estrogen. If you have a uterus and you use estrogen that is absorbed throughout the body, a progestogen is typically included to counter estrogen's effect on the lining of the uterus. Estrogen without a progestogen raises the risk of uterine cancer in people who have a uterus. Local vaginal estrogen, used for genital or urinary symptoms, is a different situation and does not automatically follow the same pairing rule; that decision belongs in a visit.
"Progesterone products" in a dispensing dataset may include several kinds of progestogen, not only one brand or one route. The JAMA figures, as reported, do not tell you which product you should use. If you have a uterus and systemic estrogen is on the table, it is reasonable to ask a clinician whether a progestogen is part of the plan, why, and what the alternatives are if you cannot take one. If you have had a hysterectomy, the conversation is different again. Those are clinical questions, not something to settle from a national trend line.
Planning around the patch shortage
Increased demand is the reason FDA gives for some estrogen patches being hard to find; that fits with the rise in dispensing, though the JAMA analysis did not measure patch availability. FDA, in an update dated September 3, 2026, and rechecked for this draft, said it is aware of reports of patients having difficulty readily accessing their usual estradiol transdermal patches due to increased demand, and that it is working with all six manufacturers to increase supply. Availability of certain products or brands may vary by pharmacy or location, FDA said, but estradiol transdermal patches "remain available." Over the last year, it said, the supply of FDA-approved estradiol transdermal patches has "nearly doubled." FDA also tells patients not to stop or change a medication without talking with a healthcare provider.
We covered what that access problem looks like in practice, what FDA has and has not declared, and what to ask a pharmacist or clinician, in our November 16 post, When estrogen patches are hard to find. That guide remains the place to go for the steps. This post does not repeat them. The short version is: do not stretch, split, share, or substitute hormone therapy on your own, and do not wait out a gap without advice. If your usual patch is delayed, a pharmacist and a clinician can help you look at another approved patch, a different schedule, or another route when that is appropriate. If you have a uterus and you change from a patch to another systemic estrogen, a progestogen typically still belongs in the plan.
A rise in national dispensing does not tell you whether your pharmacy will have your prescription this week. It does mean you are not the only person running into this, and that planning ahead with a clinician is reasonable.
Where Kindr fits
At Kindr Health, menopause and midlife care is clinician-led. If you are trying to decide whether hormone therapy belongs in the conversation, which route may be a fit, or how to plan if a patch is delayed, a licensed clinician can take a history and talk through what may or may not be appropriate. Kindr Care patient intake is open now.
This article is for educational purposes only and is not medical advice. Talk with your clinician before starting, stopping, or changing any medication. See our medical disclaimer.
Sources
- Sarnak DO, Shen W, Alexander GC, "Trends in Menopause Hormone Therapy," JAMA, published online November 19, 2026 — doi.org/10.1001/jama.2026.22619
- Aimee Cunningham, "U.S. demand for menopause hormone therapy has more than doubled recently," Science News, November 19, 2026 — www.sciencenews.org/article/menopause-hormone-therapy-demand-up
- FDA, "FDA Update on Estradiol Transdermal Patch Availability," September 3, 2026 — www.fda.gov/drugs/drug-alerts-and-statements/fda-update-estradiol-transdermal-patch-availability
- ACOG, "ACOG Expands Recommendations for Management of Menopause Symptoms," October 15, 2026 — www.acog.org/news/2026/10/acog-expands-recommendations-for-management-of-menopause-symptoms
- ACOG Clinical Practice Guideline 13, "Management of Menopause-Related Vasomotor, Sleep, and Mood Symptoms" — www.acog.org/clinical/guidance/clinical-practice-guideline/2026/11/management-of-menopause-related-vasomotor-sleep-and-mood-symptoms
- 988 Suicide & Crisis Lifeline — 988lifeline.org
Medically reviewed by Kindr Health Clinical Team
Last updated: November 20, 2026
Continue across the Kindr entity graph
Related evidence, peptides, and clinical tools on the same topic.
- Is HRT safe?Journal
- When to start HRTJournal
- Menopause HRT serviceMedication
- Complete menopause guideJournal
This content is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.